

Press release

NutriLeads attracts Series B funding to launch its innovative immune-enhancing ingredient, Xtramune™, and to progress its portfolio of health ingredients

3 September, 2020 - Wageningen, The Netherlands

Dutch Health Ingredients company, NUTRILEADS BV, announces the closing of a Series B financing round of 6.5 m€, led by ICOS CAPITAL together with GOEIE-GRUTTEN and existing shareholders DSM VENTURING, OOST NL, SHIFT INVEST and THUJA.

NutriLeads, established in 2012, develops innovative natural food ingredients with clinically proven health benefits for application in dietary supplements and functional foods. Its proprietary lead ingredient, Xtramune™, is a unique carrot-derived fibre supporting immune function and resistance to respiratory infections.

This series B funding round marks a new phase for the company. Together with global partners in the food and supplement industry, NutriLeads will be driving Xtramune™ towards commercialization in 2021. In addition, two other ingredients from its portfolio, targeting gut health and metabolic health, will be progressed to proof of concept in humans.

Ruud Albers, CEO of NutriLeads indicates: *“We are very excited about this successful funding round which helps to propel NutriLeads forward. People can strengthen their health with nutrition. It is our ambition to unlock the potential of clinically proven food ingredients and this funding round supports that mission. It is great to see that all our investors are committed to this shared goal.”*

Nityen Lal, Managing Director of ICOS Capital Management BV: *“Health ingredients are sought-after by food companies and their consumers. NutriLeads has impressed us by its professionalism, the quality of the work done and their network in the industry. We are confident that this is a worthwhile investment both for our LPs as well as for the consumers who will benefit from the health ingredients to be marketed.”*



NutriLeads, established in 2012, is a Health Ingredients company identifying and developing plant-derived food ingredients with a clinically proven positive impact on human health. All of our novel proprietary ingredients undergo clinical trials to demonstrate their efficacy in improving human health and are taken through regulatory approval ready for market access. We partner with ingredient suppliers and food and dietary supplement companies, interested in adding our Health Ingredients into their own products to make our ingredients available to the consumers.

For more information about NutriLeads please contact:

Erik Dam

CBO, NutriLeads B.V.

+31 (0)611 70 85 25

Erik.Dam@NutriLeads.com

www.nutrileads.com



Icos Capital is a European venture capital firm headquartered in Rotterdam, The Netherlands focused on investment propositions that promote sustainability of human beings and their environment. Icos Capital is investing in collaborative partnership with leading European corporations Cosun, Bühler Group and Nouryon.

For more information about Icos Capital please contact:

Nityen Lal, Managing Director

+316 2822 9932

nlal@icoscapital.com

<http://www.icoscapital.com>



Goeie Grutten Impact Fonds is an impact investment fund focused on sustainable energy transition and healthy, sustainable and balanced food. With our experienced team, we aim to support investee companies with the ideal blend of capital and management and marketing support and where needed we assist companies in achieving their intended impact targets.

For more information about Goeie Grutten Impact Fund please contact:

Kee Koopmans, Investment Manager

+316 3194 3394

kee@goeie-grutten.nl



Thuja Capital Management (Thuja) manages several venture capital funds aimed at building and scaling companies in the fields of (bio)pharmaceuticals, medtech and digital health. In addition to generating a financial return for its investors, Thuja's investments positively impact the health and well-being of patients. Thuja serves physicians and patients worldwide by providing capital to daring entrepreneurs with ground-breaking product concepts locally. Thuja's investment team consists of seasoned investors and entrepreneurs with a proven track record. Consistently performing in the top quartile, the team has backed and helped to build several of today's unicorns, as a first investor in Galapagos, Argenx and Nightbalance.

For more information about Thuja please contact:

Michel Briejer, PhD. Managing partner

+31 (0)622 46 29 27

mb@thujacapital.com

www.thujacapital.com



About DSM Venturing

DSM Venturing is the corporate venturing arm of DSM, a global, purpose-led, science-based company active in Nutrition, Health and Sustainable Living. DSM's purpose is to create brighter lives for all. DSM addresses with its products and solutions some of the world's biggest challenges while simultaneously creating economic, environmental and societal value for all its stakeholders – customers, employees, shareholders, and society at large. DSM delivers innovative solutions for human nutrition, animal nutrition, personal care and aroma, medical devices, green products and applications, and new mobility and connectivity. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 23,000 employees. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.

East Netherlands
Development Agency



Oost NL (East Netherlands Development Agency) is an agency that focuses its activities and projects on strengthening and stimulating the economy of the provinces of Gelderland and Overijssel, the Netherlands. Oost NL supports starting and growth-phase SMEs. We do this partly with risk capital from various revolving innovation funds, and partly through our knowledge, networks and personal contacts. Through the revolving funds we provide for direct as well as indirect investment and take care of the fund management. In addition, we stimulate and support public and private investors. The result: growth through financing.

For more information about Oost NL please contact
Bart Hoeflaak, team manager Food,
+ 31 (0)6 - 20 30 13 13
bart.hoeflaak@oostnl.nl
www.oostnl.nl or www.oostnl.com



SHIFT INVEST

SHIFT INVEST is a Dutch venture capital fund that invests in innovations related to the food & agriculture value chain, healthy nutrition and clean (bio-based) technologies. Through our investments, we strive to create environmental sustainability or health impact alongside financial return. Within our food&health theme, SHIFT focus is on innovations related to high quality healthy food, consumption and lifestyle. SHIFT's team, together with the fund partners Wageningen UR, Menzis, TU Delft, Rabobank and WWF, offer entrepreneurs a broad network and knowledge of the sector.

For more information about SHIFT Invest please contact:
Florentine Fockema Andreae – Fokma Investment Partner
+31 (0)610 98 08 79
Florentine.fockema@nbi-investors.nl
www.shiftinvest.com